Antiemetic effects of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin- and apomorphine-induced emesis in dogs

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 974-979

  Furukawa, Takako Yoshino ^a   Nakayama, Hiroe ^a   Kikuchi, Aya ^a   Imazumi, Katsunori ^a   Yamakuni, Hisashi ^a   Sogabe, Hajime ^a   Yamasaki, Sachiko ^a   Takeshita, Koji ^a   Matsuo, Masahiko ^a   Manda, Toshitaka ^a   Uchida, Wataru ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Apomorphine; Cisplatin; Dog; Emesis; FK886; Neurokinin 1 antagonist

Indexed keywords

[3,5 BIS(TRIFLUOROMETHYL)PHENYL][2 (3 HYDROXY 4 METHYLBENZYL) 4 [2 [2 (METHOXYMETHYL)MORPHOLIN 4 YL]ETHYL]PIPERAZIN 1 YL]METHANONE; APOMORPHINE; CISPLATIN; FK 886; GRANISETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INHIBITION; EXPERIMENTAL DOG; FEMALE; MALE; NONHUMAN; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTIEMETICS; APOMORPHINE; CISPLATIN; DOGS; FEMALE; MALE; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; PIPERAZINES; VOMITING;

EID: 84878835370     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01079     Document Type: Article

References (30)

1. Maggi CA, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol., 13, 23-93 (1993).
2. Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int. J. Biochem. Cell Biol., 28, 721-738 (1996).
3. Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin. Drug Metab. Toxicol., 5, 1607-1614 (2009).
4. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs, 69, 1853-1878 (2009).
5. Diemunsch P, Joshi GP, Brichant JF. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br. J. Anaesth., 103, 7-13 (2009).
6. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology, 33, 259-260 (1994).
7. 1 receptor antagonist GR203040. Br. J. Pharmacol., 116, 3158-3163 (1995).
8. 1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br. J. Pharmacol., 119, 931-936 (1996).
9. 1 receptor, and potent broadspectrum anti-emetic activity. Regul. Pept., 65, 45-53 (1996).
10. 1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Eur. J. Pharmacol., 321, 209-216 (1997).
11. 1 receptor. Br. J. Pharmacol., 115, 84-94 (1995).
12. 1 receptor antagonist, in ferrets. Eur. J. Pharmacol., 305, 181-185 (1996).
13. 1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology, 39, 652-663 (2000).
14. Tanihata S, Oda S, Kakuta S, Uchiyama T. Antiemetic effect of a tachykinin NK1 receptor antagonist GR205171 on cisplatin-induced early and delayed emesis in the pigeon. Eur. J. Pharmacol., 461, 197-206 (2003).
15. Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can. J. Physiol. Phar macol., 68, 325-345 (1990).
16. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology, 35, 1121-1129 (1996).
17. 1 receptor antagonists. Eur. J. Pharmacol., 326, 201-209 (1997).
18. Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem. Rev., 109, 3158-3199 (2009).
19. 1 receptor in the brainstem in the development of emesis. J. Pharmacol. Sci., 91, 87-94 (2003).
20. Yoshino-Furukawa T, Maeda Y, Kikuchi A, Sakuma H, Imazumi K, Yamakuni H, Sogabe H, Matsuo M, Manda T, Uchida W. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist. Biol. Pharm. Bull., 36, 76-81 (2013).
21. Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T, Mutoh S. Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur. J. Pharmacol., 442, 273-278 (2002).
22. 3-receptor antagonist, in ferrets and dogs. Jpn. J. Pharmacol., 57, 387-395 (1991).
23. Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T. Moment Analysis Program available on Microsoft Excel. Xenobiotic Metabolism and Disposition, 14, 286-293 (1999).
24. 3 receptor antagonist BRL 43694. Br. J. Cancer, 58, 644-650 (1988).
25. 3 receptor antagonist granisetron (BRL 43694). Brain Res., 565, 231-236 (1991).
26. De Jonghe BC, Horn CC. Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am. J. Physiol. Regul. Integr. Comp. Physiol., 296, R902-R911 (2009).
27. Chin CL, Fox GB, Hradil VP, Osinski MA, McGaraughty SP, Skoubis PD, Cox BF, Luo Y. Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: relevance as a potential biomarker for detecting drug-induced emesis. Neuroimage, 33, 1152-1160 (2006).
28. 1) receptors and increases ERK1/2- and PKA-phosphorylation during peak immediate- and delayed-phase emesis in the least shrew (Cryptotis parva) brainstem. Eur. J. Pharmacol., 698, 161-169 (2013).
29. Huskey SE, Dean BJ, Bakhtiar R, Sanchez RI, Tattersall FD, Rycroft W, Hargreaves R, Watt AP, Chicchi GG, Keohane C, Hora DF, Chiu SH. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab. Dispos., 31, 785-791 (2003).
30. 3-receptor antagonist, on chemotherapeutic agent-induced emesis. Jpn. J. Pharmacol., 63, 377-383 (1993).